MA35336B1 - Bloqueurs des canaux sodiques voltage-dependants - Google Patents
Bloqueurs des canaux sodiques voltage-dependantsInfo
- Publication number
- MA35336B1 MA35336B1 MA36731A MA36731A MA35336B1 MA 35336 B1 MA35336 B1 MA 35336B1 MA 36731 A MA36731 A MA 36731A MA 36731 A MA36731 A MA 36731A MA 35336 B1 MA35336 B1 MA 35336B1
- Authority
- MA
- Morocco
- Prior art keywords
- voltage
- respiratory diseases
- sodium channel
- channel blockers
- dependent sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne, en général, l'utilisation de composés bloqueurs des canaux sodiques voltage-dépendants qui comprennent des précurseurs, des intermédiaires, des monomères et des dimères correspondants; des compositions pharmaceutiques correspondantes; la préparation des composés; et des méthodes de traitement des maladies respiratoires et des maladies des voies respiratoires. L'invention concerne également en particulier des méthodes et des utilisations permettant de traiter des maladies respiratoires et des maladies des voies respiratoires, qui consistent à administrer une quantité efficace du composé de l'invention à un sujet le nécessitant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161505075P | 2011-07-06 | 2011-07-06 | |
PCT/US2012/045350 WO2013006596A1 (fr) | 2011-07-06 | 2012-07-03 | Bloqueurs des canaux sodiques voltage-dépendants |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35336B1 true MA35336B1 (fr) | 2014-08-01 |
Family
ID=47437403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36731A MA35336B1 (fr) | 2011-07-06 | 2014-02-05 | Bloqueurs des canaux sodiques voltage-dependants |
Country Status (20)
Country | Link |
---|---|
US (1) | US20140121213A1 (fr) |
EP (1) | EP2729149A4 (fr) |
JP (1) | JP2014518281A (fr) |
KR (1) | KR20140059774A (fr) |
CN (1) | CN103764148A (fr) |
AR (1) | AR087053A1 (fr) |
AU (1) | AU2012279091A1 (fr) |
BR (1) | BR112014000259A2 (fr) |
CA (1) | CA2840394A1 (fr) |
CL (1) | CL2014000020A1 (fr) |
CO (1) | CO6821963A2 (fr) |
CR (1) | CR20140002A (fr) |
DO (1) | DOP2014000001A (fr) |
EA (1) | EA201490210A1 (fr) |
MA (1) | MA35336B1 (fr) |
MX (1) | MX2014000112A (fr) |
PE (1) | PE20141385A1 (fr) |
TW (1) | TW201302707A (fr) |
WO (1) | WO2013006596A1 (fr) |
ZA (1) | ZA201309533B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013122897A1 (fr) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
BR112015022385A2 (pt) | 2013-03-14 | 2017-07-18 | Daiichi Sankyo Co Ltd | droga para uma doença respiratória |
US10668067B2 (en) | 2016-07-20 | 2020-06-02 | Amgen Inc. | Pyridine sulfonamides |
CN109796402A (zh) * | 2018-12-28 | 2019-05-24 | 京博农化科技有限公司 | 一种烟嘧磺隆中间体2-氯-n,n-二甲基烟酰胺的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147864A2 (fr) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Procédés d'utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium |
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
-
2012
- 2012-07-03 EP EP12806889.7A patent/EP2729149A4/fr not_active Withdrawn
- 2012-07-03 CA CA2840394A patent/CA2840394A1/fr not_active Abandoned
- 2012-07-03 WO PCT/US2012/045350 patent/WO2013006596A1/fr active Application Filing
- 2012-07-03 CN CN201280041598.8A patent/CN103764148A/zh active Pending
- 2012-07-03 AU AU2012279091A patent/AU2012279091A1/en not_active Abandoned
- 2012-07-03 BR BR112014000259A patent/BR112014000259A2/pt not_active IP Right Cessation
- 2012-07-03 KR KR1020147002808A patent/KR20140059774A/ko not_active Application Discontinuation
- 2012-07-03 MX MX2014000112A patent/MX2014000112A/es unknown
- 2012-07-03 EA EA201490210A patent/EA201490210A1/ru unknown
- 2012-07-03 US US14/128,704 patent/US20140121213A1/en not_active Abandoned
- 2012-07-03 PE PE2014000011A patent/PE20141385A1/es not_active Application Discontinuation
- 2012-07-03 JP JP2014519247A patent/JP2014518281A/ja active Pending
- 2012-07-04 AR ARP120102419A patent/AR087053A1/es unknown
- 2012-07-04 TW TW101124063A patent/TW201302707A/zh unknown
-
2013
- 2013-12-17 CO CO13294535A patent/CO6821963A2/es not_active Application Discontinuation
- 2013-12-18 ZA ZA2013/09533A patent/ZA201309533B/en unknown
-
2014
- 2014-01-02 DO DO2014000001A patent/DOP2014000001A/es unknown
- 2014-01-06 CR CR20140002A patent/CR20140002A/es unknown
- 2014-01-06 CL CL2014000020A patent/CL2014000020A1/es unknown
- 2014-02-05 MA MA36731A patent/MA35336B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201309533B (en) | 2014-08-27 |
PE20141385A1 (es) | 2014-10-29 |
EA201490210A1 (ru) | 2014-05-30 |
JP2014518281A (ja) | 2014-07-28 |
EP2729149A1 (fr) | 2014-05-14 |
CO6821963A2 (es) | 2013-12-31 |
TW201302707A (zh) | 2013-01-16 |
KR20140059774A (ko) | 2014-05-16 |
CL2014000020A1 (es) | 2014-08-01 |
AU2012279091A1 (en) | 2014-01-16 |
CR20140002A (es) | 2014-03-05 |
CN103764148A (zh) | 2014-04-30 |
US20140121213A1 (en) | 2014-05-01 |
BR112014000259A2 (pt) | 2017-02-14 |
EP2729149A4 (fr) | 2015-01-07 |
AR087053A1 (es) | 2014-02-12 |
MX2014000112A (es) | 2014-01-31 |
DOP2014000001A (es) | 2014-04-30 |
CA2840394A1 (fr) | 2013-01-10 |
WO2013006596A1 (fr) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35836B1 (fr) | 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1 | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
MA35336B1 (fr) | Bloqueurs des canaux sodiques voltage-dependants | |
EA201290919A1 (ru) | Индазольные соединения и их применение | |
MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
MA35920B1 (fr) | Composés destinés au traitement de l'amyotrophie spinale | |
EA201290644A1 (ru) | Блокаторы натриевых потенциал-зависимых каналов | |
GEP20166438B (en) | Imidazopyrrolidinone compounds | |
EA201690033A2 (ru) | Морфинановые соединения | |
MA32907B1 (fr) | Régime posologique d'un agoniste du récepteur s1p | |
MA32981B1 (fr) | Regime posologique pour un agoniste du recepteur s1p | |
MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
EA200970706A1 (ru) | Новые фармацевтические композиции | |
EA200970512A1 (ru) | Лечение по поводу множественной миеломы | |
EA201201541A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ | |
EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA35407B1 (fr) | Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine |